Press releases

Filter by year:

GeNeuro reports cash and revenue for Q3 2017

Geneva, Switzerland, 2 November 2017 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis and type-1 diabetes, reported today its cash and revenues for the third quarter 2017.

GeNeuro to Host Conference Call and Webcast Today Following the Presentation of Promising Post-Hoc Analyses at the MSParis2017 Congress

Geneva, Switzerland, 30 October 2017 at 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, reported promising post-hoc analyses of six-month data from CHANGE-MS Phase 2b study at MSParis2017 on Saturday October 28th and will hold a conference call and webcast today.

GeNeuro and Servier Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017

Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results showed an anti-inflammatory effect in active patients at the highest (18 mg/kg) of the three doses tested at Week 24. In addition, at the same dose, a promising effect on remyelination was observed at 24 weeks.

GeNeuro Reports 2017 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, 28 September 2017 at 06:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, today reported its half-year financial results for the period ending June 30, 2017 and provided a corporate update.

GeNeuro and Servier to Present Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis at MSParis2017

Geneva, Switzerland, and Paris, France - 19 Septembre 2017 at 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today that 6-month data from the CHANGE-MS Phase 2b study will be presented at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS meeting held 25-28 October 2017, in Paris, France. The presentation will cover efficacy and safety data, and will include post-hoc analyses supporting the hypothesis of a

GeNeuro and Collaborators Publish Data Supporting Role of Retroviral Pathogenic Envelope Protein in Type 1 Diabetes (T1D)

Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that data supporting the role of pathogenic pHERV-W env in Type 1 diabetes has been published in The Journal of Clinical Investigation Insight. Pathogenic pHERV-W env is encoded by a member of the HERV-W family. HERVs are ancestral retroviral DNA insertions in the human genome, thought to account for up to 8% of the human genome.

GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis

Geneva, Switzerland, and Paris, France, 28 August 2017 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today 6-month results from the 12-month CHANGE-MS Phase 2b study of three doses of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

GeNeuro updates on cash, revenue and activities at Q2 2017

Genève, Switzerland, 31 July 2017 - 6:00pm CEST : GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis and type-1 diabetes, reports today on its cash and revenues for the second quarter 2017 and provides an update on its activities.

GeNeuro Announces First Patient Treated in Phase 2a Study with GNbAC1 in Type 1 Diabetes

Geneva, Switzerland, 19 June 2017 - 7:30am CEST : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that the first patient has been treated in its Australian Phase 2a study of GNbAC1 in type 1 diabetes. This is GNbAC1’s second indication after multiple sclerosis, for which an international Phase 2b study is ongoing in 260 patients.

GeNeuro Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs) in Type 1 Diabetes at American Diabetes Association (ADA) Scientific Sessions

Geneva (Switzerland), 12 june 2017 - 7:30am CEST : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today data supporting the link between human endogenous retroviruses (HERVs) and Type 1 diabetes (T1D). Data were presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA (June 9-13, 2017).


Results 1-10 of 16      Next Page      Last Page